Pharmaceutical

Nuntius partners with Taiho to develop mRNA cancer therapies

UK-based biotechnology company Nuntius Therapeutics has announced a strategic collaboration agreement with Japan’s Taiho Pharmaceutical to develop next-generation messenger ribonucleic acid (mRNA) cancer immunotherapies.

Aug 17, 2024 - 04:00
Nuntius partners with Taiho to develop mRNA cancer therapies
UK-based biotechnology company Nuntius Therapeutics has announced a strategic collaboration agreement with Japan’s Taiho Pharmaceutical to develop next-generation messenger ribonucleic acid (mRNA) cancer immunotherapies.
Read the original article

Tags:

Previous Article

The Genomic Medicine Revolution: Multi-Modality Approaches in Advanced Therapies 

Next Article

AstraZeneca’s sBLA for LS-SCLC treatment gains FDA priority review

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

From data to action: Igniting the healthcare revolution

From data to action: Igniting the healthcare revolution

Jun 30, 2024

Eli Lilly boosts sales forecast by $3bn as diabetes and weight loss drugs propel revenue

Eli Lilly boosts sales forecast by $3bn as diabetes and...

Aug 11, 2024

Parliamentarians call on G7 leaders to invest in neglected tropical diseases

Parliamentarians call on G7 leaders to invest in neglec...

May 18, 2023